Downregulation of GATA6 in mTOR-inhibited human aortic endothelial cells: effects on TNF-α-induced VCAM-1 expression and monocytic cell adhesion.


Journal

American journal of physiology. Heart and circulatory physiology
ISSN: 1522-1539
Titre abrégé: Am J Physiol Heart Circ Physiol
Pays: United States
ID NLM: 100901228

Informations de publication

Date de publication:
01 02 2019
Historique:
pubmed: 22 11 2018
medline: 28 12 2019
entrez: 22 11 2018
Statut: ppublish

Résumé

Increased expression of vascular cell adhesion molecule 1 (VCAM-1) on the aortic endothelium is an early marker of atherogenesis, promoted in part by elevated levels of inflammatory cytokines such as TNF-α. Mammalian target of rapamycin (mTOR) is a ubiquitous signaling molecule that has been considered to contribute to diverse cellular processes through mTOR complex 1 (mTORC1) or complex 2 (mTORC2). This study aimed to elucidate the role of mTOR signaling in TNF-α-induced VCAM-1 expression by the arterial endothelium. Primary human aortic endothelial cells (HAECs) were treated with low-dose (0.1 ng/ml) TNF-α, and VCAM-1 expression was measured by real-time quantitative PCR, Western blot analysis, and flow cytometry. Inhibition of mTOR through siRNA-mediated depletion or treatment with chemical inhibitors rapamycin or torin 1 suppressed VCAM1 transcription, which translated to inhibition of VCAM-1 surface expression by HAECs and concomitant decreased adhesion of monocytes. A promoter luciferase assay and chromatin immunoprecipitation indicated that mTOR regulated VCAM1 transcription through a mechanism involving transcription factor GATA6. Activation of PKC-α and an increase in miR-200a-3p expression, caused by mTOR inhibition but not disruption of mTORC1 or mTORC2 singly or together, decreased TNF-α-induced GATA6 expression and its enrichment at the VCAM1 promoter. In conclusion, mTOR inhibition activates PKC-α independently of disruption of mTORC1 and/or mTORC2, which challenges the conventional wisdom regarding mTOR signaling. Moreover, mTOR signals through transcriptional and posttranscriptional mechanisms to elicit maximal cytokine-induced endothelial inflammation that precedes atherosclerosis. NEW & NOTEWORTHY Both mammalian target of rapamycin (mTOR) complex 1 (mTORC1) and mTORC2 contribute to PKC-α activation in the human aortic endothelium. Inhibition of mTOR is not equivalent to disruption of mTORC1 and/or mTORC2 in affecting human aortic endothelial cell signaling. Specifically, inhibition of mTOR causes PKC-α activation and miR-200a-3p upregulation, which independently suppresses TNF-α-induced transcription factor GATA6 expression and subsequently inhibits VCAM-1 expression and monocytic cell adhesion onto the aortic endothelium.

Identifiants

pubmed: 30462552
doi: 10.1152/ajpheart.00411.2018
pmc: PMC6397389
doi:

Substances chimiques

GATA6 Transcription Factor 0
GATA6 protein, human 0
Tumor Necrosis Factor-alpha 0
Vascular Cell Adhesion Molecule-1 0
TOR Serine-Threonine Kinases EC 2.7.11.1
Protein Kinase C-alpha EC 2.7.11.13

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

H408-H420

Subventions

Organisme : NCI NIH HHS
ID : P30 CA093373
Pays : United States

Références

Atherosclerosis. 2008 May;198(1):39-48
pubmed: 17980369
EMBO J. 2008 Jul 23;27(14):1919-31
pubmed: 18566587
Circ Res. 1999 Jul 23;85(2):199-207
pubmed: 10417402
Cancer Res. 2007 Sep 15;67(18):8699-707
pubmed: 17875710
J Immunol. 2004 Aug 1;173(3):2041-9
pubmed: 15265939
Atherosclerosis. 2016 May;248:97-109
pubmed: 26994427
Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9902-7
pubmed: 19497867
J Exp Med. 1996 Jul 1;184(1):173-82
pubmed: 8691131
J Cell Biol. 2015 Oct 12;211(1):105-22
pubmed: 26459601
J Exp Med. 2014 Mar 10;211(3):395-404
pubmed: 24516119
Nat Rev Immunol. 2007 Sep;7(9):678-89
pubmed: 17717539
Adv Exp Med Biol. 2015;887:79-100
pubmed: 26662987
Pharmacogenomics. 2013 Sep;14(12):1517-26
pubmed: 24024901
J Immunol. 2008 Jun 1;180(11):7516-24
pubmed: 18490752
Curr Biol. 2004 Jul 27;14(14):1296-302
pubmed: 15268862
Cell Metab. 2008 Nov;8(5):411-24
pubmed: 19046572
Atherosclerosis. 2004 Jan;172(1):31-8
pubmed: 14709354
Cancer Res. 2010 Jan 15;70(2):621-31
pubmed: 20068177
Cell. 2012 Apr 13;149(2):274-93
pubmed: 22500797
Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):917-22
pubmed: 11397697
Circ Res. 2012 Sep 28;111(8):1054-64
pubmed: 22874466
Hepatology. 2009 Aug;50(2):472-80
pubmed: 19585654
J Biol Chem. 2009 Sep 4;284(36):24341-53
pubmed: 19553685
J Clin Invest. 2011 Jun;121(6):2197-209
pubmed: 21606591
Mol Cell Biol. 2010 Feb;30(4):908-21
pubmed: 19995915
Nature. 2005 Feb 3;433(7025):477-80
pubmed: 15690031
Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2137-42
pubmed: 15345516
Oncotarget. 2017 Jan 17;8(3):4747-4759
pubmed: 27902469
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2072-2077
pubmed: 28167758
Methods Mol Biol. 2012;821:447-60
pubmed: 22125084
J Immunol. 2005 May 1;174(9):5823-9
pubmed: 15843586
J Pharmacol Exp Ther. 2009 Feb;328(2):419-25
pubmed: 19023042
PLoS One. 2016 Jan 11;11(1):e0146777
pubmed: 26752047
Genes Cells. 2004 Apr;9(4):359-66
pubmed: 15066126
Curr Opin Hematol. 2018 May;25(3):227-236
pubmed: 29547400
J Clin Invest. 2014 Jun;124(6):2696-708
pubmed: 24762440
J Cell Biol. 2013 Apr 15;201(2):293-308
pubmed: 23569215
Mol Cell. 2006 Apr 21;22(2):159-68
pubmed: 16603397
Atherosclerosis. 2010 Nov;213(1):115-21
pubmed: 20864106
J Clin Invest. 2001 May;107(10):1255-62
pubmed: 11375415
J Cell Biol. 2009 Dec 14;187(6):859-74
pubmed: 20008564

Auteurs

Xing Fan (X)

Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University , Nanjing , China.

Xiaolin Chen (X)

Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University , Nanjing , China.

Qi Feng (Q)

Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University , Nanjing , China.

Kai Peng (K)

Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University , Nanjing , China.

Qianqian Wu (Q)

Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University , Nanjing , China.

Anthony G Passerini (AG)

Department of Biomedical Engineering, University of California , Davis, California.

Scott I Simon (SI)

Department of Biomedical Engineering, University of California , Davis, California.

ChongXiu Sun (C)

Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University , Nanjing , China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH